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Comparison of genomic alterations 
between primary breast cancer and 
remnant breast or ipsilateral chest wall 
recurrence 
According to domestic and worldwide statistics, breast cancer is the most common 
cancer in females. With advancement in sequencing technique and targeted therapy 
based on genomic information, to identify targetable genomic abnormalities is 
becoming more common. However, it remains challenging to optimize treatment for 
the patients with second breast malignancies after receiving treatment of primary 
cancers, without better understanding on the differences between primary and 
relapsed tumors. Herein, we assessed genomic properties between primary and 
recurrent tumors of ipsilateral breast or chest wall after curative resection. When 
we compared the results of targeted next-generation exon sequencing with 121 
cancer-related genes on formalin-fixed paraffin-embedded (FFPE) matched 
samples from 20 patients, genomic alterations showed highly concordant between 
paired samples, regardless of clinicopathological manifestation known as a factors 
impacting on recurrent tumors’ attributes such as the interval to relapse, change of 
molecular subtype and therapeutic interventions. The analysis based on targeted 
exome sequencing results revealed that most of primary tumors and matched local 
recurrences clustered together and had strong positive linear correlation. We found 
that 16 out of 20 patients had at least one shared somatic mutation or CNAs between 
the primary and local recurrence, and the gain or loss of alterations throughout tumor 
progression developed in 8 patients, 1 case of whom acquired new driver mutations 
that could be targets for breast cancer.  




primary tumor and matched local recurrence using next-generation sequencing. We 
found the molecular characteristics consistently retained in majority of local 
recurrence within the territory of remnant breast or ipsilateral chest wall, showing 
small number of changes in driver mutations. Based on this findings, genomic 
profiling on primary cancer may give useful information when considering target 
therapy in patients with local recurrence.  
---------------------------------------- 
Keyword: breast cancer, local recurrence, genomic alteration, next-generation 
sequencing (NGS) 
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Breast cancer remains the leading cause of cancer-related mortality in 
worldwide(1). Although approximately 80% of patients diagnosed breast cancer 
with early stage and most women with localized disease is amenable to curative 
therapy, significant proportions of patients suffer from recurrence (2, 3). Breast 
cancer recurrence may occur in the ipsilateral remnant breast or chest wall where 
primary cancer was originally diagnosed and resected, regional lymph nodes as well 
as distant sites. Developing local recurrence does not always herald distant 
metastases but regarded as the high risk of subsequent distant relapse and poor 
prognosis (4). Several reports have suggested that local recurrence at the site of 
ipsilateral breast or chest wall is regarded as true recurrence (TR) consistent with 
the regrowth of remained malignant cells, which is an independent predictor of 
distant metastatic disease and poor survival(5, 6). Others have indicated, however, 
new primary tumor (NPT) described as “de novo malignancies” just gave rise to at 
the very site previously resected, that it showed quite different features with 
previously treated primary tumors(7-9). Several studies have attempted to classify 
these differences by using tumor location at recurrence, histologic subtype or 
pathologic criteria(8, 10). Some researchers suggested a genetic classification 
using clonal analysis, genomic expression profiling or quantitative DNA 
fingerprinting as a potentially valuable tool to improve understanding for the second 
breast malignancies(11-13).  
With advancement in genomic analysis technique and getting genomic data of the 
tumors more frequently, genomic alteration 
s throughout tumor progression may provide an insight helpful for comprehending 
the features of the relapsing tumors and determining appropriate treatment after 
recurrence. Genomic evolution have been increasingly studied and have showed that 




to acquire or lose mutations (14). As recent clinical trials enable to select targeted 
drugs based on genomic information for tailored therapy, genomic profiling has 
become more important, especially in recurrence or treatment-resistant cancers. 
The aim of this study is to compare genomic information and targetable genomic 
changes in both of primary tumors and local recurrence lesions through targeted 
sequencing of cancer-related genes, it might be useful when determining 
therapeutic target agents for recurrent tumors. 
 
Patients and Methods 
Tumor samples and clinicopathologic information  
We reviewed the records of patients with invasive breast cancer who underwent 
operations for both of primary and relapsed tumor from 2002 to 2015 at the Seoul 
National University Hospital (Seoul, South Korea). Patients were selected on 
basis of primary-local recurrent matched tissue availability. Formalin-fixed 
paraffin blocks in both of primary breast cancer and matched recurrent tumor 
specimens were obtained. The Formalin fixed paraffin embedded (FFPE) samples 
were evaluated by a pathologist for selection of tumor areas for microdissection. 
To exclude germline mutations, we further sequenced the selected patients’ 
blood sample if it had been stocked in our biorepository (Repository of lab of 
breast cancer biology, Seoul National University Hospital, IRB number: 1405-
088-580). DNA was purified and extracted using ReliaPrep™ FFPE gDNA 
Miniprep System (Promega) and the quality of DNA was assessed through a 
TapeStation Systems according to the manufacturer’s instructions. We 
confirmed DNA purity as ratio of A260/A280 is between 1.8 and 2.0. 
Clinicopathologic information including immunohistochemistry and Fluorescence 




medical records. The location of relapsed tumors which were documented in 
medical records or identified in mammography were obtained whether the tumor 
recurred at or near the vicinity of the primary tumor site. This study was approved 
by the Institutional Review Board of Seoul National University Hospital (IRB 
number: 1712-150-911).  
Immunohistochemistry (IHC) staining and interpretation  
This method was previously used in a published study (15). The samples were 
immunostained with the following antibodies according to the manufacturers' 
instructions: Anti-estrogen receptor(ER) (1:100; 1D5; Dako, Glostrup, Denmark), 
anti-progesterone receptor (PgR) (1:100; 636; Dako), and anti-HER2 (1:200; 
A0485; Dako). Positive ER and PgR expression were defined as nuclear staining 
in 1% or more of tumor cells. The HER2 membranous staining was scored on a 
scale of 0 to 3+ according to the HercepTest protocol. For tissue samples with a 
human epidermal growth factor receptor-2 (HER2) staining score of 2+, 
additional HER2 FISH testing was considered. HER2 status was considered 
positive when the IHC score was 3+ or the gene copy ratio of HER2/CEP17 by 
FISH was 2.2 or higher.  
Genomic profiling 
We performed a targeted next-generation sequencing (NGS) assay on FFPE 
samples by using a multi-gene panel (SNUH BCC (Seoul National University 
Hospital Breast Care Center) Panel) with average 356X sequencing depth. The 
SNUH BCC panel consisting of 121 genes was developed based on our previous 
study in which we had performed whole-exome sequencing and RNA-Seq of 200 
pairs of matched clinical breast cancer and normal samples from Korean breast 
cancer patients. In addition, we had analyzed the mutations, CNAs, and gene 
expression results of approximately 3000 clinical breast cancer samples in the 




suppressor genes, or breast cancer-associated genes that showed a highly 
frequent mutations, genomic copy number variations and expression changes in 
breast cancer tissues (Table 1). The SNUH BCC panel is unique compared with 
other cancer panels based on NGS because it includes a certain portion of novel 
breast cancer-associated genes that have not been included in other recent 
popular and conventional cancer panels. In this regard, the SNUH BCC panel is not 
only targeted to worldwide breast cancer patients but is also ethnically directed to 
Korean breast cancer patients for diagnosis and therapeutic prognostic prediction 
(16).  
Sequence alignment, variant calling and driver landscape for 
therapeutic target 
Raw FASTQ file was filtered and trimmed using Adaptor removal 2.2.2. Burrows-
Wheeler aligner (BWA; version 0.7.10) mem with default option was used to align 
reads to human reference genome sequence GRCh37. Sequence alignment map 
(SAM) file was converted to BAM format using samtools (version 1.1). Picard 
tool (version 1.115) was used to sort and remove duplications. GATK (version 
4.0.4.0) was used to perform base quality score re-calibration. Samtools mpileup 
was used to create mpileup file with minimum base-quality of 17 and varscan 
(version 2.4.0) was used to call variants. Minimum variant frequency was set to 
1%, minimum coverage was set to 8, minimum supporting reads was set to 2, and 
Strand-filter was applied. We excluded germline SNVs as well as technical 
artifacts observed in the blood samples and known variants from public databases 
such as the Genome Aggregation Database (gnomAD) and 1000 Genomes. And 
then variations were filtered by using the dbSNP archive (http://www.ncbi. 
nlm.nih.gov/projects/ SNP/) and annotated for known somatic mutations by using 
the COSMIC (17, 18). Somatic copy number alterations (CNAs) were called by 
calculating the number of mapped reads and then performing normalization using 




and for loss <0.25-fold. Each variant is classified according to the Association of 
Molecular Pathology (AMP) guidelines for somatic cancer variants (19). Any 
variants classified as benign, likely benign or variants with unknown significance 
(VUS) were excluded for driver mutation landscape. We considered known 
oncogenic/likely oncogenic variants and hotspots as reported in the literature so 
far, and we defined alterations deemed a target of FDA-approved drug or 
investigational therapeutics on basis of a review of TARGET database v3 in 
Cancer Genome Analysis (CGA) and oncology knowledge database (OncoKB) 
database as “actionable”(20, 21). Actionable alterations with clinical or biologic 
evidence supporting an association with response to targeted drugs were 
stratified by level of evidence from OncoKB. We used “R version 4.0.1” to compare 
and visualize the differences and similarities between primary tumors and 
matched recurrence. The results from paired samples that can be sequenced with 
high quality were included in calculation to well visualize the patterns of matched 
samples. MutationMapper was used for visualization of actionable mutations. (22) 
 
Results 
Patient and sample characteristics 
The clinicopathological characteristics of the 20 patients in our study were 
summarized at Figure 1 and we described more detail information in Table 2 and 
3. The mean age at primary breast cancer diagnosis was 48.6 years (range 37–70) 
and median follow-up period from the date of primary cancer diagnosis to last visit 
record to our clinic was 146 months. The mean local recurrence free interval was 
32 months (range 6–108). Twelve patients (60%) were diagnosed with hormone 
receptor (HR) positive primary breast cancer including 3 patients with unknown 




triple negative primary breast cancer (TNBC;ER-, PR-, and HER2-negative) 
were 4(20%) and 5(25%), respectively. At presentation with primary cancer, 8 
patients (40%) had axillary lymph node metastasis and 16 women received 
neoadjuvant/adjuvant chemotherapy. As the sites of relapse were defined 
according to surgery type, recurrence at remnant breast (50%) for the patients 
who underwent breast conserving surgery (BCS) and ipsilateral chest walls (50%) 
for mastectomy. Eight patients developed subsequent distant metastasis, and two 
showed synchronous metastatic lesion with local recurrence (Figure 1, Table 2).  
When comparing molecular types of the primary and matched recurrent lesions, 
local recurrence mostly had concordant immunohistochemical characteristics [i.e. 
hormone receptors (HR) and HER2 status] with that of primary tumor. All triple-
negative and HER-2 status retained their characteristics in the matched recurrent 
lesions, whereas 4 patients appeared to have discordant ER or PgR status. More 
specifically, three patients lost ER or PgR during progression and 1 recurrent 
tumor gained PgR. (Table 2, 3). 
Somatic mutations and copy number variations of primary tumors 
and local recurrence  
In 40 FFPE samples, we identified a total of 90 driver somatic alterations or copy 
number variations (CNVs) in 25 genes (Figure 1). There is no germline mutation 
in 16 blood samples. Genomic sequencing using the 121-gene panel detected at 
least one known oncogenic or likely oncogenic alteration in 36 of 40 samples (mean 
2.25; range, 0–6). In the manner of copy number calculation from NGS data, as 
ERBB2 gain were observed in the 8 of the 10 tumors that were identified as HER2-
positive by IHC or FISH, so the HER2 copy-number amplification results were 
found to be discordant with that of tested by IHC or FISH  in 2 cases (Figure 1). 
The most frequently mutated gene was TP53 (23.3%), followed by PIK3CA 




PIK3CA gene. When we excluded the tumors with unknown IHC results, TP53 
alterations were found in 87.5% out of triple-negative samples, 50% in HER2-
positive samples, and 43.5% in HR-positive samples. Whereas, PIK3CA alterations 
were observed in 60.9% of HR-positive tumors and only 1 of HR-negative 
samples. At least one alteration was detected in 6 genes associated with clinical 
action irrespective of the kind of targeted tumor type, excluding amplifications in 
ERBB2 gene (Figure 1 & Table 3).  
Comparison of genomic properties in primary tumors and matched 
local recurrence 
The unsupervised hierarchical clustering of the tumors based on genomic 
mutations revealed that 17 pairs out of 20 matched samples clustered together 
(Figure 2A). Additional correlation analysis of 18 patients excluding 2 pairs with 
low sample quality showed the recurrent tumors’ genomic characteristics were 
closely related with that of primary lesions with respect to targeted analysis 
(Pearson’s correlation, Figure 2B). 
In a driver perspective, 54 (83.1%) of the 65 somatic mutations and 18 (72%) of 
25 CNVs detected were found to be concordant in primary cancer and matched 
recurrence (Figure 3). Eight patients showed differences in genomic alterations 
between primary tumors and recurrence, 6 relapsed tumors of whom acquired 
deleterious alterations compared to primary tumors.  
Clinicopathological features and genomic concordance  
When we calculated Z score to assess and visualize genomic similarities among 
samples, the matched samples were mostly concordant regardless of tumor 
location or molecular subtype (Figure 4, Table 3). Though all pairs were composed 
of a same histologic subtype with invasive ductal carcinomas in most cases and 




occurred in remnant breasts was located at a site different from the primary 
(Patient#6). Of the 12 patients with HR-positive tumors at initial diagnosis, in 
terms of molecular subtypes, 3 patients revealed changes of HR status but retained 
either of ER or PR positivity in recurrent tumors and conversion to HR-negative 
subtype occurred in one patient (Patient #13). Furthermore, local recurrence free 
interval ranged from 6 to 108 months, showing over 7 years interval in two patients 
(Patient #5 and #6). Figure 4 showed that genomic features of matched recurrent 
tumors were highly concordant with those of primary tumors in Patient #5, #6 and 
#13. The paired samples in these 3 patients had also identical driver mutations 
and CNVs (Figure 3). Additionally, recurrent tumor showed similarity with the 
primary tumor in 17 patients who had received adjuvant therapy, 16 women of 
whom received cytotoxic chemotherapy (Figure 4, Table 3).  
Clinical actionability of molecular targets  
Overall, 15 of the 20 patients had genomic alterations in approved or potentially 
“actionable” genes including HER2 amplifications. With exception of HER2 
amplifications, genomic profiling detected new potentially actionable alterations 
that had not been previously identified by standard-of care testing in 14 patients. 
The targets identified were listed in Table 5. Oncogenic mutations in PIK3CA gene 
were most frequently detected for therapeutic target. Somatic mutations in 
CDKN2A (p. G101L and p. N42Rfs) and FGFR2 (p. F276V) genes were considered 
as likely oncogenic changes in well-known functional protein domain that regulate 
the cell growth or division (Figure 5)(23, 24). We found somatic alterations in six 
genes with breast cancer-specific or all solid tumor-acceptable target drugs, 
whereas two (FLT3 and SF3B1) of targetable genes have not yet be approved for 
breast cancer (Table 4). Six patients subsequently suffered metachronous distant 
metastasis after receiving treatment for local recurrence. Whereas only one 
recurrent tumor (patient #14) showed new targetable genomic alteration in 




showed consistent results between primary and recurrent tumors from an 
actionable point of view. 
 
Discussion 
Personalized therapy is based on molecular characterization of the tumor and target 
aberrations that drive tumor growth(25). As the NGS techniques and target therapy 
based on genomic information have been advanced, the genetic landscape allows 
tailored therapy and will overcome tumoral heterogeneity and its resistance to 
traditional anticancer agents (26, 27).  
Breast cancer is a highly heterogeneous disease; the same primary tumor 
frequently showed different genomic profiles and its recurrent lesion also acquired 
new molecular aberrations compared to their primary tumors. While several studies 
have showed the result on genomic evolution between primary breast cancer and 
its’ metastasis (14, 28-30), we studied genomic alterations confined to local 
recurrence in remnant breast or chest wall where primary tumor had been removed. 
With respect to ipsilateral breast tumor recurrence, many studies have been tried 
to classify the new primary and true recurrence on basis of clinical features such 
as histology, molecular subtype or location between primary and relapsed tumors. 
To our knowledge, this is the first study comparing between primary tumor and 
matched local recurrence based on genomic analysis using sequencing data.  
We performed target sequencing of 121 cancer-related genes to evaluate and 
compare the spectrum of genomic alterations between primary breast cancer and 
matched local recurrence in remnant breast or ipsilateral chest wall after 
mastectomy. A large proportion of primary and matched recurrent tumors included 
in our analysis seemed to have similar genomic properties irrespective of 




alterations. Previous studies have considered clinical and molecular features like 
as different histology, tumor occurrence at distant site from primary tumor bed and 
molecular subtype discordance as an indicator to distinguish between de novo 
primary tumor and regrowth of remained malignant cell and to impact on post-
recurrence survival and potential treatment options(31). We identified, however, 
secondary cancer developed in remnant breast or chest wall was found as true 
recurrence rather than new primary tumor, retaining their genomic characteristics 
of primary cancer even when recurrent tumor occurred at a different site with long 
periods after primary cancer treatment or with changes in molecular types. 
Moreover, new primary tumors were known to be developed after a longer interval 
from their initial treatment than patients with true recurrence, but recurrent lesions 
developed after long period over than 7 and 9 years in two patients had similar 
attributes to those of primary tumors.  
Previous studies have presented that somatic alterations were more frequently 
found in recurrent lesions than primary tumors, especially in the analysis focused 
on distant metastasis (14, 28, 29). However, our result suggested that local relapse 
within the area of remnant breast or ipsilateral chest wall had similar attributes 
with primary cancer, and significant evolution throughout local relapse rarely 
happened (Figure 4). Yates et al revealed genomic evolution exerted by 
therapeutic interventions response to treatment exposures, as truncating 
mutations were gained after chemotherapy or cancer genes potentially actionable 
driver mutations emerged during endocrine therapy(14). When we gave 
consideration that most of patients included in our study had received systemic 
adjuvant therapy (chemotherapy and/or hormone therapy) or radiotherapy for local 
control, however, overall genomic properties of relapsed tumors did not seem to 
be affected by therapeutic interventions. 
In terms of actionable genomic mutations, one patient acquired driver mutation 




PIK3CA gene) and targetable mutation in CDKN2A gene emerged in the other one 
case(Patient #8). Because the quality of primary FFPE sample in case of Patient#8 
was definitely poor and was sequenced with very low depth coverage, there are 
limitation to interpret the differences. The amplifications in CNK12 gene and SNVs 
in FLT3 and SF3B1 which were described in Table 5 might be potential candidates 
related with clinical action with limited evidence, for targeted mutation type or 
tumor type are different from those of literatures.  
Our study has several limitations. The number of cases included in this study is 
small, for obtaining both of primary tumor and matched FFPE block was challenging. 
Limited sample size resulted in the failure of the comprehensive statistical analysis 
on the correlation between genomic alterations and clinical characteristics such as 
subtypes or disease-free interval. Additionally, as our study was designed as 
retrospective manner and the samples had not collected with purpose of genomic 
analysis, the quality of FFPE samples varied depending on the archived periods or 
status of storage. It might have affected the sequencing result reducing coverage 
depth in certain region or increasing the rate of variants detected in some of the 
samples. For these reasons, we consequently applied very strict cut-offs both of 
depth and allelic frequency for the confirmation of NGS variant calls. Finally, this 
study limited to perform targeted sequencing only focused on genomic mutations 
and CNVs and did not analyze other abnormalities in DNA methylation or 
phosphorylation, gene fusion, RNA or protein expression that can provide novel 
information. Further comprehensive analysis integrating the genomic profiles, 
tumor biology and clinical information is essential for better understanding.   
In conclusion, we found that genomic characteristics of primary tumor 
consistently retained in majority of local recurrence within the territory of remnant 
breast or ipsilateral chest wall, showing small number of changes in driver 
alterations. So genomic profiling on primary cancer is thought to provide useful 










Figure 2 Comparison of genomic features in primary tumors and matched local recurrence. A, Unsupervised hierarchical clustering 
of samples based on genomic mutations revealed that 17 pairs out of 20 matched samples clustered together. B, Pearson’s correlation 
showed strong positive relation between primary and matched recurrent lesions. The paired samples of Patient #8 and #9 were excluded 





Figure 3 Visualization on an example of concordant copy number variation detected in our series. Gain of copy number in CDK12 





Figure 4 Bar graph representing clusters of primary and matched relapsed tumors in terms of Z scores. Z score plot showed 
each of matched samples clustered regardless of clinical properties. (Samples with high quality sequencing (;>80% in 100x coverage) 
included only in this bar graph.) Patient #5 & #6 had long recurrence free interval, 108 and 95 months respectively. Recurrence 
developed at a different location of remnant breast compared with the site of primary cancer in Patient #6, and Patient #13 revealed 





Figure 5 Identification of therapeutic target of functional protein domain or hotspot. The lollipop plot shows mutation in functional 




Table 1 List of 121 cancer related gene panel 
ABL1 CDH1 EZH2 INPP4B MRE11A PTEN ZNF703 
ABL2 CDK12 FANCD2 INSR MST1R PTK2   
AKT1 CDK4 FBXW7 IRS2 MTOR PTK6   
AKT2 CDK6 FGF3 JAK1 MYC RB1   
AKT3 CDKN1B FGF4 JAK2 NAV3 RET   
ALK CDKN2A FGFR1 JAK3 NCOR1 ROS1   
APC CDKN2B FGFR2 KDM5B NF1 RPS6KB1   
AR CTCF FGFR3 KIT NOTCH1 RUNX1   
ARID1A CTNNB1 FGFR4 KMT2C NOTCH2 SETD2   
ATM DDR1 FLT3 KMT2D NOTCH3 SF3B1   
ATR DDR2 FLT4 KRAS PAK1 SRC   
AURKA EGFR FOXA1 LTK PARP1 STK11   
AURKB EIF4EBP1 FOXM1 MALAT1 PDGFRA SYK   
BRAF EP300 GATA3 MAP2K4 PDGFRB TBX3   
BRCA1 EPHA2 GNAS MAP3K1 PIK3CA TLR4   
BRCA2 EPHA3 IDH1 MAP4K5 PIK3CG TOP2A   
C11orf30 ERBB2 IDH2 MCL1 PIK3R1 TP53   
CBFB ERBB3 IGF1R MDM2 PIK3R3 TSC2   
CCND1 ERBB4 IGF2R MEN1 POLQ TYK2   




















Local recurrence site    
 Remnant breast          10 (50%) 
  Chest wall 
(tumor bed) 
       10 (50%) 
Tumor size   
  ≤ 2cm  12 (60%) 13 (65%) 
  > 2cm 8 (40%) 6 (30%) 
       Unknown  0 1 (5%) 
Axillary nodal status    
Node negative 12 (60%) 5 (25%) 
Node positive 8 (40%) 7 (35%) 
Unknown  8 (40%) 
AJCC stage (8th edition)   
I 9 (45%)  
II 9 (45%)      
III 2 (10%)  
Histologic type   
ductal carcinoma 19 (95%) 19 (95%) 
lobular carcinoma 1 (5%) 1 (5%) 
Subtype   
HR+/HER2- 7 (35%) 5 (25%) 
HR+/HER2+ 2 (10%) 3 (15%) 
HR-/HER2+ 2 (10%) 3 (15%) 
TNBC 5 (25%) 3 (15%) 
HR+/HER2unknown 3 (15%) 3 (15%) 
HR-/HER2unknown 1(5%) 1(5%) 
Unknown 0 2(10%) 
Hormone Receptor   
Positive 12 (60%) 11 (55%) 




Unknown 0 2 (10%) 
Histologic grade   
1 0 1 (5%) 
2 4 (20%) 5 (25%) 
3 15 (75%) 11 (55%) 
unknown 1 (5%) 3 (15%) 
Ki-67   
Low (<10%) 9 (45%) 11 (55%) 
High (≥10%) 10 (50%) 5 (25%) 
Unkonwn 1 (5%) 4 (20%) 
Surgery-Breast   
Mastectomy 10 (50%) 7 (35%) 
Breast conservation 10 (50%) 0 
Tumor excision 0 13 (65%) 
Surgery-Axilla   
SLNBx* Only 7 (35%) 1 (5%) 
ALND** 14 (65%) 8 (40%) 
Others*** 0 11 (55%) 




16 (80%)  
Radiotherapy 8 (40%)  
Hormone therapy 10 (50%)  
*The cutoff value of Ki-67 is 10% (32).   
* SLNBx; Sentinel lymph node biopsy **ALND; axillary lymph node dissection   





















Patient#5 56 chest wall Rt upper RUO ER+ PR-             CMF, TMF  108 
     ER+ PR+    
Patient#12 48 chest wall Lt inner Lt upper ER+ PR+                FAC, TMX  17 
     ER- PR+    
Patient#10 46 remnant breast  RUI RUI ER+ PR+                CMF, Radiotherapy, TMF 47 
     ER+ PR+    
Patient#19 44 remnant breast  Lt upper~outer Lt subareola ER+ PR+                    Refused by patient 36 
     ER+ PR+   
Patient#6 33 remnant breast  LLI 
LLO  
(far outer) 
ER+ PR+       FAC, Radiotherapy, TMX 95 
     ER+ PR+     
Patient#15 41 chest wall Lt. subaroelar  Lt chest wall ER+ PR-               AT + D, TMX 21 
     ER+ PR-    
Patient#17 43 remnant breast  LUI LUI ER+ PR+                Refused by patient 23 
     ER+ PR+   
Patient#3 38 chest wall RUO RUO ER+ PR+       CMF, TMX 32 
     ER+ PR-     
Patient#11 64 chest wall Rt outer RUO ER+ PR-                AT + T, Arimidex 34 
     ER+ PR-   
Patient#18 54 chest wall LUI Lt chest wall ER+ PR- Femara 8 
     ER+ PR-    
Patient#9 70 chest wall Rt upper Rt chest wall  ER+ PR-                CMF, arimidex 31 
     ER+ PR-   




     ER- PR-   
Patient#4 42 chest wall Rt upper 
Along previous 
scar 
ER- PR-              Adjuvant EC + Doxetaxol  11 
     ER- PR-   
Patient#7 35 remnant breast  LLI LLI ER- PR-             FAC, Radiotherapy 26 
     ER- PR-    




     ER- PR-   
Patient#20 54 remnant breast  RUI RUI ER- PR-                FAC, Radiotherapy 9 
     ER- PR-    
Patient#16 37 remnant breast  Lt subareolar  Lt subareola ER- PR-                AT + D, Radiotherapy 14 
     ER- PR-    
Patient#1 40 remnant breast  LUO 
Lt outer, 
periareolar 
ER- PR-             CMF, Radiotherapy 49 
     ER- PR-    
Patient#2 56 remnant breast  Rt outer Rt outer ER- PR-  AC + Taxol, Radiotherapy 6 
     N/A   
Patient#8 70 chest wall LUO LUO ER- PR-               FAC 10 
     N/A   










Amino acid change 












































(G101W is known 


































#4 Primary FLT3 V643I 
Acute Myeloid 
Leukemia 













(no evidence in 
solid tumor) 
H3B-8800 [4] 
* Multiple mutations in one patient ** Acquired new alteration in recurrent tumor that did 
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유방암 수술 후 국소 재발암과 원발암의 유전적 변이 비교 
국내외 통계에 따르면 유방암은 여성에서 발생하는 암 중 가장 흔한 암이다. 유전자 분
석 기술과 유방암의 유전 정보에 기초한 표적 치료는 지속적으로 발전하고 있어 치료의 
표적이 되는 유전적 이상(genomic alterations)을 확인하는 것이 임상적으로 중요하다. 
그러나 원발암의 치료 후 발생하는 재발암의 경우 원발암에 비해 유전적 정보에 대한 연
구 결과가 부족하고, 치료에 대한 내성이 발생한 기전 등을 고려해야 하기 때문에 맞춤
형 치료를 제시하는 것이 더욱 어렵다. 유방암의 원발 종양과 재발암에서 나타나는 유전
적 변화를 확인하기 위해 우리는 유방암의 근치적 치료를 받은 후 동측의 잔존 유방 및 
흉벽의 국소 재발을 경험한 20명의 원발암과 재발암 조직에 대해 121개의 암 관련 유
전자를 이용하여 차세대 염기 서열 분석(Next-generation sequencing, NGS)을 시행하
였다. 원발암과 동측의 유방 혹은 흉벽에 재발한 종양의 유전적 특성을 분석한 결과 동
일한 환자에서 발생한 원발암-재발암 조직은 매우 유사한 결과를 보였다. 일부 연구에
서 재발암 발생 위치나 분자 아형과 같은 임상학적/분자적 특성의 변화가 발생한 경우나, 
무병 기간이 긴 경우 원발암의 특성과는 완전히 다른 특성을 가진 재발암이 발생할 확률
이 높은 것이 보고되었으나, 본 연구에서는 무병기간, 아형, 항암 화학 요법, 호르몬 요
법 및 방사선 치료 등과 같은 임상적 요소와 관계없이 재발암의 유전적 변이는 원발암의 
유전적 변이와 매우 유사한 것으로 나타났다. 또한 대부분의 환자 (80%)에서 원발암과 
국소 재발암은 적어도 1개 이상의 동일한 driver alteration(somatic mutation 또는 
CNV)을 공유했으며, 재발암이 발생하면서 유전자 변이가 변화(gain or loss)를 보였던 
8명의 환자 중 재발암에서 유방암 치료의 타겟이 될 수 있는 새로운 driver mutation을 
발견한 것은 1명이었다.  
본 연구는 원발암-재발암 조직의 차세대 염기 서열 분석법을 이용하여 원발암과 동측의 
잔존 유방 및 흉벽의 국소 재발암의 유전적 특성을 비교한 첫 번째 연구로, 분석 결과 
짝지어진 조직의 유전적 특성은 매우 유사한 것으로 확인되었다. 따라서 원발암 조직의 




공할 것으로 생각된다. 
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Comparison of genomic alterations 
between primary breast cancer and 
remnant breast or ipsilateral chest wall 
recurrence 
According to domestic and worldwide statistics, breast cancer is the most common 
cancer in females. With advancement in sequencing technique and targeted therapy 
based on genomic information, to identify targetable genomic abnormalities is 
becoming more common. However, it remains challenging to optimize treatment for 
the patients with second breast malignancies after receiving treatment of primary 
cancers, without better understanding on the differences between primary and 
relapsed tumors. Herein, we assessed genomic properties between primary and 
recurrent tumors of ipsilateral breast or chest wall after curative resection. When 
we compared the results of targeted next-generation exon sequencing with 121 
cancer-related genes on formalin-fixed paraffin-embedded (FFPE) matched 
samples from 20 patients, genomic alterations showed highly concordant between 
paired samples, regardless of clinicopathological manifestation known as a factors 
impacting on recurrent tumors’ attributes such as the interval to relapse, change of 
molecular subtype and therapeutic interventions. The analysis based on targeted 
exome sequencing results revealed that most of primary tumors and matched local 
recurrences clustered together and had strong positive linear correlation. We found 
that 16 out of 20 patients had at least one shared somatic mutation or CNAs between 
the primary and local recurrence, and the gain or loss of alterations throughout tumor 
progression developed in 8 patients, 1 case of whom acquired new driver mutations 
that could be targets for breast cancer.  




primary tumor and matched local recurrence using next-generation sequencing. We 
found the molecular characteristics consistently retained in majority of local 
recurrence within the territory of remnant breast or ipsilateral chest wall, showing 
small number of changes in driver mutations. Based on this findings, genomic 
profiling on primary cancer may give useful information when considering target 
therapy in patients with local recurrence.  
---------------------------------------- 
Keyword: breast cancer, local recurrence, genomic alteration, next-generation 
sequencing (NGS) 
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Breast cancer remains the leading cause of cancer-related mortality in 
worldwide(1). Although approximately 80% of patients diagnosed breast cancer 
with early stage and most women with localized disease is amenable to curative 
therapy, significant proportions of patients suffer from recurrence (2, 3). Breast 
cancer recurrence may occur in the ipsilateral remnant breast or chest wall where 
primary cancer was originally diagnosed and resected, regional lymph nodes as well 
as distant sites. Developing local recurrence does not always herald distant 
metastases but regarded as the high risk of subsequent distant relapse and poor 
prognosis (4). Several reports have suggested that local recurrence at the site of 
ipsilateral breast or chest wall is regarded as true recurrence (TR) consistent with 
the regrowth of remained malignant cells, which is an independent predictor of 
distant metastatic disease and poor survival(5, 6). Others have indicated, however, 
new primary tumor (NPT) described as “de novo malignancies” just gave rise to at 
the very site previously resected, that it showed quite different features with 
previously treated primary tumors(7-9). Several studies have attempted to classify 
these differences by using tumor location at recurrence, histologic subtype or 
pathologic criteria(8, 10). Some researchers suggested a genetic classification 
using clonal analysis, genomic expression profiling or quantitative DNA 
fingerprinting as a potentially valuable tool to improve understanding for the second 
breast malignancies(11-13).  
With advancement in genomic analysis technique and getting genomic data of the 
tumors more frequently, genomic alteration 
s throughout tumor progression may provide an insight helpful for comprehending 
the features of the relapsing tumors and determining appropriate treatment after 
recurrence. Genomic evolution have been increasingly studied and have showed that 




to acquire or lose mutations (14). As recent clinical trials enable to select targeted 
drugs based on genomic information for tailored therapy, genomic profiling has 
become more important, especially in recurrence or treatment-resistant cancers. 
The aim of this study is to compare genomic information and targetable genomic 
changes in both of primary tumors and local recurrence lesions through targeted 
sequencing of cancer-related genes, it might be useful when determining 
therapeutic target agents for recurrent tumors. 
 
Patients and Methods 
Tumor samples and clinicopathologic information  
We reviewed the records of patients with invasive breast cancer who underwent 
operations for both of primary and relapsed tumor from 2002 to 2015 at the Seoul 
National University Hospital (Seoul, South Korea). Patients were selected on 
basis of primary-local recurrent matched tissue availability. Formalin-fixed 
paraffin blocks in both of primary breast cancer and matched recurrent tumor 
specimens were obtained. The Formalin fixed paraffin embedded (FFPE) samples 
were evaluated by a pathologist for selection of tumor areas for microdissection. 
To exclude germline mutations, we further sequenced the selected patients’ 
blood sample if it had been stocked in our biorepository (Repository of lab of 
breast cancer biology, Seoul National University Hospital, IRB number: 1405-
088-580). DNA was purified and extracted using ReliaPrep™ FFPE gDNA 
Miniprep System (Promega) and the quality of DNA was assessed through a 
TapeStation Systems according to the manufacturer’s instructions. We 
confirmed DNA purity as ratio of A260/A280 is between 1.8 and 2.0. 
Clinicopathologic information including immunohistochemistry and Fluorescence 




medical records. The location of relapsed tumors which were documented in 
medical records or identified in mammography were obtained whether the tumor 
recurred at or near the vicinity of the primary tumor site. This study was approved 
by the Institutional Review Board of Seoul National University Hospital (IRB 
number: 1712-150-911).  
Immunohistochemistry (IHC) staining and interpretation  
This method was previously used in a published study (15). The samples were 
immunostained with the following antibodies according to the manufacturers' 
instructions: Anti-estrogen receptor(ER) (1:100; 1D5; Dako, Glostrup, Denmark), 
anti-progesterone receptor (PgR) (1:100; 636; Dako), and anti-HER2 (1:200; 
A0485; Dako). Positive ER and PgR expression were defined as nuclear staining 
in 1% or more of tumor cells. The HER2 membranous staining was scored on a 
scale of 0 to 3+ according to the HercepTest protocol. For tissue samples with a 
human epidermal growth factor receptor-2 (HER2) staining score of 2+, 
additional HER2 FISH testing was considered. HER2 status was considered 
positive when the IHC score was 3+ or the gene copy ratio of HER2/CEP17 by 
FISH was 2.2 or higher.  
Genomic profiling 
We performed a targeted next-generation sequencing (NGS) assay on FFPE 
samples by using a multi-gene panel (SNUH BCC (Seoul National University 
Hospital Breast Care Center) Panel) with average 356X sequencing depth. The 
SNUH BCC panel consisting of 121 genes was developed based on our previous 
study in which we had performed whole-exome sequencing and RNA-Seq of 200 
pairs of matched clinical breast cancer and normal samples from Korean breast 
cancer patients. In addition, we had analyzed the mutations, CNAs, and gene 
expression results of approximately 3000 clinical breast cancer samples in the 




suppressor genes, or breast cancer-associated genes that showed a highly 
frequent mutations, genomic copy number variations and expression changes in 
breast cancer tissues (Table 1). The SNUH BCC panel is unique compared with 
other cancer panels based on NGS because it includes a certain portion of novel 
breast cancer-associated genes that have not been included in other recent 
popular and conventional cancer panels. In this regard, the SNUH BCC panel is not 
only targeted to worldwide breast cancer patients but is also ethnically directed to 
Korean breast cancer patients for diagnosis and therapeutic prognostic prediction 
(16).  
Sequence alignment, variant calling and driver landscape for 
therapeutic target 
Raw FASTQ file was filtered and trimmed using Adaptor removal 2.2.2. Burrows-
Wheeler aligner (BWA; version 0.7.10) mem with default option was used to align 
reads to human reference genome sequence GRCh37. Sequence alignment map 
(SAM) file was converted to BAM format using samtools (version 1.1). Picard 
tool (version 1.115) was used to sort and remove duplications. GATK (version 
4.0.4.0) was used to perform base quality score re-calibration. Samtools mpileup 
was used to create mpileup file with minimum base-quality of 17 and varscan 
(version 2.4.0) was used to call variants. Minimum variant frequency was set to 
1%, minimum coverage was set to 8, minimum supporting reads was set to 2, and 
Strand-filter was applied. We excluded germline SNVs as well as technical 
artifacts observed in the blood samples and known variants from public databases 
such as the Genome Aggregation Database (gnomAD) and 1000 Genomes. And 
then variations were filtered by using the dbSNP archive (http://www.ncbi. 
nlm.nih.gov/projects/ SNP/) and annotated for known somatic mutations by using 
the COSMIC (17, 18). Somatic copy number alterations (CNAs) were called by 
calculating the number of mapped reads and then performing normalization using 




and for loss <0.25-fold. Each variant is classified according to the Association of 
Molecular Pathology (AMP) guidelines for somatic cancer variants (19). Any 
variants classified as benign, likely benign or variants with unknown significance 
(VUS) were excluded for driver mutation landscape. We considered known 
oncogenic/likely oncogenic variants and hotspots as reported in the literature so 
far, and we defined alterations deemed a target of FDA-approved drug or 
investigational therapeutics on basis of a review of TARGET database v3 in 
Cancer Genome Analysis (CGA) and oncology knowledge database (OncoKB) 
database as “actionable”(20, 21). Actionable alterations with clinical or biologic 
evidence supporting an association with response to targeted drugs were 
stratified by level of evidence from OncoKB. We used “R version 4.0.1” to compare 
and visualize the differences and similarities between primary tumors and 
matched recurrence. The results from paired samples that can be sequenced with 
high quality were included in calculation to well visualize the patterns of matched 
samples. MutationMapper was used for visualization of actionable mutations. (22) 
 
Results 
Patient and sample characteristics 
The clinicopathological characteristics of the 20 patients in our study were 
summarized at Figure 1 and we described more detail information in Table 2 and 
3. The mean age at primary breast cancer diagnosis was 48.6 years (range 37–70) 
and median follow-up period from the date of primary cancer diagnosis to last visit 
record to our clinic was 146 months. The mean local recurrence free interval was 
32 months (range 6–108). Twelve patients (60%) were diagnosed with hormone 
receptor (HR) positive primary breast cancer including 3 patients with unknown 




triple negative primary breast cancer (TNBC;ER-, PR-, and HER2-negative) 
were 4(20%) and 5(25%), respectively. At presentation with primary cancer, 8 
patients (40%) had axillary lymph node metastasis and 16 women received 
neoadjuvant/adjuvant chemotherapy. As the sites of relapse were defined 
according to surgery type, recurrence at remnant breast (50%) for the patients 
who underwent breast conserving surgery (BCS) and ipsilateral chest walls (50%) 
for mastectomy. Eight patients developed subsequent distant metastasis, and two 
showed synchronous metastatic lesion with local recurrence (Figure 1, Table 2).  
When comparing molecular types of the primary and matched recurrent lesions, 
local recurrence mostly had concordant immunohistochemical characteristics [i.e. 
hormone receptors (HR) and HER2 status] with that of primary tumor. All triple-
negative and HER-2 status retained their characteristics in the matched recurrent 
lesions, whereas 4 patients appeared to have discordant ER or PgR status. More 
specifically, three patients lost ER or PgR during progression and 1 recurrent 
tumor gained PgR. (Table 2, 3). 
Somatic mutations and copy number variations of primary tumors 
and local recurrence  
In 40 FFPE samples, we identified a total of 90 driver somatic alterations or copy 
number variations (CNVs) in 25 genes (Figure 1). There is no germline mutation 
in 16 blood samples. Genomic sequencing using the 121-gene panel detected at 
least one known oncogenic or likely oncogenic alteration in 36 of 40 samples (mean 
2.25; range, 0–6). In the manner of copy number calculation from NGS data, as 
ERBB2 gain were observed in the 8 of the 10 tumors that were identified as HER2-
positive by IHC or FISH, so the HER2 copy-number amplification results were 
found to be discordant with that of tested by IHC or FISH  in 2 cases (Figure 1). 
The most frequently mutated gene was TP53 (23.3%), followed by PIK3CA 




PIK3CA gene. When we excluded the tumors with unknown IHC results, TP53 
alterations were found in 87.5% out of triple-negative samples, 50% in HER2-
positive samples, and 43.5% in HR-positive samples. Whereas, PIK3CA alterations 
were observed in 60.9% of HR-positive tumors and only 1 of HR-negative 
samples. At least one alteration was detected in 6 genes associated with clinical 
action irrespective of the kind of targeted tumor type, excluding amplifications in 
ERBB2 gene (Figure 1 & Table 3).  
Comparison of genomic properties in primary tumors and matched 
local recurrence 
The unsupervised hierarchical clustering of the tumors based on genomic 
mutations revealed that 17 pairs out of 20 matched samples clustered together 
(Figure 2A). Additional correlation analysis of 18 patients excluding 2 pairs with 
low sample quality showed the recurrent tumors’ genomic characteristics were 
closely related with that of primary lesions with respect to targeted analysis 
(Pearson’s correlation, Figure 2B). 
In a driver perspective, 54 (83.1%) of the 65 somatic mutations and 18 (72%) of 
25 CNVs detected were found to be concordant in primary cancer and matched 
recurrence (Figure 3). Eight patients showed differences in genomic alterations 
between primary tumors and recurrence, 6 relapsed tumors of whom acquired 
deleterious alterations compared to primary tumors.  
Clinicopathological features and genomic concordance  
When we calculated Z score to assess and visualize genomic similarities among 
samples, the matched samples were mostly concordant regardless of tumor 
location or molecular subtype (Figure 4, Table 3). Though all pairs were composed 
of a same histologic subtype with invasive ductal carcinomas in most cases and 




occurred in remnant breasts was located at a site different from the primary 
(Patient#6). Of the 12 patients with HR-positive tumors at initial diagnosis, in 
terms of molecular subtypes, 3 patients revealed changes of HR status but retained 
either of ER or PR positivity in recurrent tumors and conversion to HR-negative 
subtype occurred in one patient (Patient #13). Furthermore, local recurrence free 
interval ranged from 6 to 108 months, showing over 7 years interval in two patients 
(Patient #5 and #6). Figure 4 showed that genomic features of matched recurrent 
tumors were highly concordant with those of primary tumors in Patient #5, #6 and 
#13. The paired samples in these 3 patients had also identical driver mutations 
and CNVs (Figure 3). Additionally, recurrent tumor showed similarity with the 
primary tumor in 17 patients who had received adjuvant therapy, 16 women of 
whom received cytotoxic chemotherapy (Figure 4, Table 3).  
Clinical actionability of molecular targets  
Overall, 15 of the 20 patients had genomic alterations in approved or potentially 
“actionable” genes including HER2 amplifications. With exception of HER2 
amplifications, genomic profiling detected new potentially actionable alterations 
that had not been previously identified by standard-of care testing in 14 patients. 
The targets identified were listed in Table 5. Oncogenic mutations in PIK3CA gene 
were most frequently detected for therapeutic target. Somatic mutations in 
CDKN2A (p. G101L and p. N42Rfs) and FGFR2 (p. F276V) genes were considered 
as likely oncogenic changes in well-known functional protein domain that regulate 
the cell growth or division (Figure 5)(23, 24). We found somatic alterations in six 
genes with breast cancer-specific or all solid tumor-acceptable target drugs, 
whereas two (FLT3 and SF3B1) of targetable genes have not yet be approved for 
breast cancer (Table 4). Six patients subsequently suffered metachronous distant 
metastasis after receiving treatment for local recurrence. Whereas only one 
recurrent tumor (patient #14) showed new targetable genomic alteration in 




showed consistent results between primary and recurrent tumors from an 
actionable point of view. 
 
Discussion 
Personalized therapy is based on molecular characterization of the tumor and target 
aberrations that drive tumor growth(25). As the NGS techniques and target therapy 
based on genomic information have been advanced, the genetic landscape allows 
tailored therapy and will overcome tumoral heterogeneity and its resistance to 
traditional anticancer agents (26, 27).  
Breast cancer is a highly heterogeneous disease; the same primary tumor 
frequently showed different genomic profiles and its recurrent lesion also acquired 
new molecular aberrations compared to their primary tumors. While several studies 
have showed the result on genomic evolution between primary breast cancer and 
its’ metastasis (14, 28-30), we studied genomic alterations confined to local 
recurrence in remnant breast or chest wall where primary tumor had been removed. 
With respect to ipsilateral breast tumor recurrence, many studies have been tried 
to classify the new primary and true recurrence on basis of clinical features such 
as histology, molecular subtype or location between primary and relapsed tumors. 
To our knowledge, this is the first study comparing between primary tumor and 
matched local recurrence based on genomic analysis using sequencing data.  
We performed target sequencing of 121 cancer-related genes to evaluate and 
compare the spectrum of genomic alterations between primary breast cancer and 
matched local recurrence in remnant breast or ipsilateral chest wall after 
mastectomy. A large proportion of primary and matched recurrent tumors included 
in our analysis seemed to have similar genomic properties irrespective of 




alterations. Previous studies have considered clinical and molecular features like 
as different histology, tumor occurrence at distant site from primary tumor bed and 
molecular subtype discordance as an indicator to distinguish between de novo 
primary tumor and regrowth of remained malignant cell and to impact on post-
recurrence survival and potential treatment options(31). We identified, however, 
secondary cancer developed in remnant breast or chest wall was found as true 
recurrence rather than new primary tumor, retaining their genomic characteristics 
of primary cancer even when recurrent tumor occurred at a different site with long 
periods after primary cancer treatment or with changes in molecular types. 
Moreover, new primary tumors were known to be developed after a longer interval 
from their initial treatment than patients with true recurrence, but recurrent lesions 
developed after long period over than 7 and 9 years in two patients had similar 
attributes to those of primary tumors.  
Previous studies have presented that somatic alterations were more frequently 
found in recurrent lesions than primary tumors, especially in the analysis focused 
on distant metastasis (14, 28, 29). However, our result suggested that local relapse 
within the area of remnant breast or ipsilateral chest wall had similar attributes 
with primary cancer, and significant evolution throughout local relapse rarely 
happened (Figure 4). Yates et al revealed genomic evolution exerted by 
therapeutic interventions response to treatment exposures, as truncating 
mutations were gained after chemotherapy or cancer genes potentially actionable 
driver mutations emerged during endocrine therapy(14). When we gave 
consideration that most of patients included in our study had received systemic 
adjuvant therapy (chemotherapy and/or hormone therapy) or radiotherapy for local 
control, however, overall genomic properties of relapsed tumors did not seem to 
be affected by therapeutic interventions. 
In terms of actionable genomic mutations, one patient acquired driver mutation 




PIK3CA gene) and targetable mutation in CDKN2A gene emerged in the other one 
case(Patient #8). Because the quality of primary FFPE sample in case of Patient#8 
was definitely poor and was sequenced with very low depth coverage, there are 
limitation to interpret the differences. The amplifications in CNK12 gene and SNVs 
in FLT3 and SF3B1 which were described in Table 5 might be potential candidates 
related with clinical action with limited evidence, for targeted mutation type or 
tumor type are different from those of literatures.  
Our study has several limitations. The number of cases included in this study is 
small, for obtaining both of primary tumor and matched FFPE block was challenging. 
Limited sample size resulted in the failure of the comprehensive statistical analysis 
on the correlation between genomic alterations and clinical characteristics such as 
subtypes or disease-free interval. Additionally, as our study was designed as 
retrospective manner and the samples had not collected with purpose of genomic 
analysis, the quality of FFPE samples varied depending on the archived periods or 
status of storage. It might have affected the sequencing result reducing coverage 
depth in certain region or increasing the rate of variants detected in some of the 
samples. For these reasons, we consequently applied very strict cut-offs both of 
depth and allelic frequency for the confirmation of NGS variant calls. Finally, this 
study limited to perform targeted sequencing only focused on genomic mutations 
and CNVs and did not analyze other abnormalities in DNA methylation or 
phosphorylation, gene fusion, RNA or protein expression that can provide novel 
information. Further comprehensive analysis integrating the genomic profiles, 
tumor biology and clinical information is essential for better understanding.   
In conclusion, we found that genomic characteristics of primary tumor 
consistently retained in majority of local recurrence within the territory of remnant 
breast or ipsilateral chest wall, showing small number of changes in driver 
alterations. So genomic profiling on primary cancer is thought to provide useful 










Figure 2 Comparison of genomic features in primary tumors and matched local recurrence. A, Unsupervised hierarchical clustering 
of samples based on genomic mutations revealed that 17 pairs out of 20 matched samples clustered together. B, Pearson’s correlation 
showed strong positive relation between primary and matched recurrent lesions. The paired samples of Patient #8 and #9 were excluded 





Figure 3 Visualization on an example of concordant copy number variation detected in our series. Gain of copy number in CDK12 





Figure 4 Bar graph representing clusters of primary and matched relapsed tumors in terms of Z scores. Z score plot showed 
each of matched samples clustered regardless of clinical properties. (Samples with high quality sequencing (;>80% in 100x coverage) 
included only in this bar graph.) Patient #5 & #6 had long recurrence free interval, 108 and 95 months respectively. Recurrence 
developed at a different location of remnant breast compared with the site of primary cancer in Patient #6, and Patient #13 revealed 





Figure 5 Identification of therapeutic target of functional protein domain or hotspot. The lollipop plot shows mutation in functional 




Table 1 List of 121 cancer related gene panel 
ABL1 CDH1 EZH2 INPP4B MRE11A PTEN ZNF703 
ABL2 CDK12 FANCD2 INSR MST1R PTK2   
AKT1 CDK4 FBXW7 IRS2 MTOR PTK6   
AKT2 CDK6 FGF3 JAK1 MYC RB1   
AKT3 CDKN1B FGF4 JAK2 NAV3 RET   
ALK CDKN2A FGFR1 JAK3 NCOR1 ROS1   
APC CDKN2B FGFR2 KDM5B NF1 RPS6KB1   
AR CTCF FGFR3 KIT NOTCH1 RUNX1   
ARID1A CTNNB1 FGFR4 KMT2C NOTCH2 SETD2   
ATM DDR1 FLT3 KMT2D NOTCH3 SF3B1   
ATR DDR2 FLT4 KRAS PAK1 SRC   
AURKA EGFR FOXA1 LTK PARP1 STK11   
AURKB EIF4EBP1 FOXM1 MALAT1 PDGFRA SYK   
BRAF EP300 GATA3 MAP2K4 PDGFRB TBX3   
BRCA1 EPHA2 GNAS MAP3K1 PIK3CA TLR4   
BRCA2 EPHA3 IDH1 MAP4K5 PIK3CG TOP2A   
C11orf30 ERBB2 IDH2 MCL1 PIK3R1 TP53   
CBFB ERBB3 IGF1R MDM2 PIK3R3 TSC2   
CCND1 ERBB4 IGF2R MEN1 POLQ TYK2   




















Local recurrence site    
 Remnant breast          10 (50%) 
  Chest wall 
(tumor bed) 
       10 (50%) 
Tumor size   
  ≤ 2cm  12 (60%) 13 (65%) 
  > 2cm 8 (40%) 6 (30%) 
       Unknown  0 1 (5%) 
Axillary nodal status    
Node negative 12 (60%) 5 (25%) 
Node positive 8 (40%) 7 (35%) 
Unknown  8 (40%) 
AJCC stage (8th edition)   
I 9 (45%)  
II 9 (45%)      
III 2 (10%)  
Histologic type   
ductal carcinoma 19 (95%) 19 (95%) 
lobular carcinoma 1 (5%) 1 (5%) 
Subtype   
HR+/HER2- 7 (35%) 5 (25%) 
HR+/HER2+ 2 (10%) 3 (15%) 
HR-/HER2+ 2 (10%) 3 (15%) 
TNBC 5 (25%) 3 (15%) 
HR+/HER2unknown 3 (15%) 3 (15%) 
HR-/HER2unknown 1(5%) 1(5%) 
Unknown 0 2(10%) 
Hormone Receptor   
Positive 12 (60%) 11 (55%) 




Unknown 0 2 (10%) 
Histologic grade   
1 0 1 (5%) 
2 4 (20%) 5 (25%) 
3 15 (75%) 11 (55%) 
unknown 1 (5%) 3 (15%) 
Ki-67   
Low (<10%) 9 (45%) 11 (55%) 
High (≥10%) 10 (50%) 5 (25%) 
Unkonwn 1 (5%) 4 (20%) 
Surgery-Breast   
Mastectomy 10 (50%) 7 (35%) 
Breast conservation 10 (50%) 0 
Tumor excision 0 13 (65%) 
Surgery-Axilla   
SLNBx* Only 7 (35%) 1 (5%) 
ALND** 14 (65%) 8 (40%) 
Others*** 0 11 (55%) 




16 (80%)  
Radiotherapy 8 (40%)  
Hormone therapy 10 (50%)  
*The cutoff value of Ki-67 is 10% (32).   
* SLNBx; Sentinel lymph node biopsy **ALND; axillary lymph node dissection   





















Patient#5 56 chest wall Rt upper RUO ER+ PR-             CMF, TMF  108 
     ER+ PR+    
Patient#12 48 chest wall Lt inner Lt upper ER+ PR+                FAC, TMX  17 
     ER- PR+    
Patient#10 46 remnant breast  RUI RUI ER+ PR+                CMF, Radiotherapy, TMF 47 
     ER+ PR+    
Patient#19 44 remnant breast  Lt upper~outer Lt subareola ER+ PR+                    Refused by patient 36 
     ER+ PR+   
Patient#6 33 remnant breast  LLI 
LLO  
(far outer) 
ER+ PR+       FAC, Radiotherapy, TMX 95 
     ER+ PR+     
Patient#15 41 chest wall Lt. subaroelar  Lt chest wall ER+ PR-               AT + D, TMX 21 
     ER+ PR-    
Patient#17 43 remnant breast  LUI LUI ER+ PR+                Refused by patient 23 
     ER+ PR+   
Patient#3 38 chest wall RUO RUO ER+ PR+       CMF, TMX 32 
     ER+ PR-     
Patient#11 64 chest wall Rt outer RUO ER+ PR-                AT + T, Arimidex 34 
     ER+ PR-   
Patient#18 54 chest wall LUI Lt chest wall ER+ PR- Femara 8 
     ER+ PR-    
Patient#9 70 chest wall Rt upper Rt chest wall  ER+ PR-                CMF, arimidex 31 
     ER+ PR-   




     ER- PR-   
Patient#4 42 chest wall Rt upper 
Along previous 
scar 
ER- PR-              Adjuvant EC + Doxetaxol  11 
     ER- PR-   
Patient#7 35 remnant breast  LLI LLI ER- PR-             FAC, Radiotherapy 26 
     ER- PR-    




     ER- PR-   
Patient#20 54 remnant breast  RUI RUI ER- PR-                FAC, Radiotherapy 9 
     ER- PR-    
Patient#16 37 remnant breast  Lt subareolar  Lt subareola ER- PR-                AT + D, Radiotherapy 14 
     ER- PR-    
Patient#1 40 remnant breast  LUO 
Lt outer, 
periareolar 
ER- PR-             CMF, Radiotherapy 49 
     ER- PR-    
Patient#2 56 remnant breast  Rt outer Rt outer ER- PR-  AC + Taxol, Radiotherapy 6 
     N/A   
Patient#8 70 chest wall LUO LUO ER- PR-               FAC 10 
     N/A   










Amino acid change 












































(G101W is known 


































#4 Primary FLT3 V643I 
Acute Myeloid 
Leukemia 













(no evidence in 
solid tumor) 
H3B-8800 [4] 
* Multiple mutations in one patient ** Acquired new alteration in recurrent tumor that did 
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유방암 수술 후 국소 재발암과 원발암의 유전적 변이 비교 
국내외 통계에 따르면 유방암은 여성에서 발생하는 암 중 가장 흔한 암이다. 유전자 분
석 기술과 유방암의 유전 정보에 기초한 표적 치료는 지속적으로 발전하고 있어 치료의 
표적이 되는 유전적 이상(genomic alterations)을 확인하는 것이 임상적으로 중요하다. 
그러나 원발암의 치료 후 발생하는 재발암의 경우 원발암에 비해 유전적 정보에 대한 연
구 결과가 부족하고, 치료에 대한 내성이 발생한 기전 등을 고려해야 하기 때문에 맞춤
형 치료를 제시하는 것이 더욱 어렵다. 유방암의 원발 종양과 재발암에서 나타나는 유전
적 변화를 확인하기 위해 우리는 유방암의 근치적 치료를 받은 후 동측의 잔존 유방 및 
흉벽의 국소 재발을 경험한 20명의 원발암과 재발암 조직에 대해 121개의 암 관련 유
전자를 이용하여 차세대 염기 서열 분석(Next-generation sequencing, NGS)을 시행하
였다. 원발암과 동측의 유방 혹은 흉벽에 재발한 종양의 유전적 특성을 분석한 결과 동
일한 환자에서 발생한 원발암-재발암 조직은 매우 유사한 결과를 보였다. 일부 연구에
서 재발암 발생 위치나 분자 아형과 같은 임상학적/분자적 특성의 변화가 발생한 경우나, 
무병 기간이 긴 경우 원발암의 특성과는 완전히 다른 특성을 가진 재발암이 발생할 확률
이 높은 것이 보고되었으나, 본 연구에서는 무병기간, 아형, 항암 화학 요법, 호르몬 요
법 및 방사선 치료 등과 같은 임상적 요소와 관계없이 재발암의 유전적 변이는 원발암의 
유전적 변이와 매우 유사한 것으로 나타났다. 또한 대부분의 환자 (80%)에서 원발암과 
국소 재발암은 적어도 1개 이상의 동일한 driver alteration(somatic mutation 또는 
CNV)을 공유했으며, 재발암이 발생하면서 유전자 변이가 변화(gain or loss)를 보였던 
8명의 환자 중 재발암에서 유방암 치료의 타겟이 될 수 있는 새로운 driver mutation을 
발견한 것은 1명이었다.  
본 연구는 원발암-재발암 조직의 차세대 염기 서열 분석법을 이용하여 원발암과 동측의 
잔존 유방 및 흉벽의 국소 재발암의 유전적 특성을 비교한 첫 번째 연구로, 분석 결과 
짝지어진 조직의 유전적 특성은 매우 유사한 것으로 확인되었다. 따라서 원발암 조직의 




공할 것으로 생각된다. 
주요어: 유방암, 국소 재발, 유전자 변이, 차세대 염기 서열 분석법 
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